Clinical trials: Treatment-Refractory Schizophrenia
Schizophrenia, Hallucinations, Auditory
fMRI-based Neurofeedback to Relieve Drug-resistant Auditory Hallucinations
The INTRUDE trial aims at assessing the efficacy of an fMRI-based neurofeedback procedure on drug-resistant auditory hallucinations.
- Conditions
- Schizophrenia, Hallucinations, Auditory, Hallucinations, Visual
- Trial name
- INTRUDE (NCT04798131)
- Testing
- Active neurofeedback procedure
- Where
- France
- Volunteers
- 84 people
- Sponsor
- University Hospital, Lille
Schizophrenia, Forensic Psychiatry
Dundrum Forensic Redevelopment Evaluation Study: D-FOREST Study.
The DUNDRUM Forensic Redevelopment Evaluation study (D-FOREST study) is a multi-site comprehensive evaluation of a complete National Forensic Mental Health Service.
- Conditions
- Schizophrenia, Forensic Psychiatry, Outcome Measure, Violence
- Trial name
- D-FOREST (NCT05074732)
- Where
- Ireland
- Volunteers
- 350 people
- Sponsor
- Health Service Executive, Ireland
Schizophrenia
A Study Comparing the Efficacy and Tolerability of Ziprasidone vs. Clozapine for the Treatment of Schizophrenia in Patients Who Continue to Have Symptoms on or Cannot Tolerate Other Antipsychotic Drugs
The purpose of this study is to compare the efficacy and safety of ziprasidone and clozapine in schizophrenic patients who are resistant and/or intolerant to antipsychotic treatment
- Trial name
- MOZART (NCT00649844)
- Testing
- Clozapine, Ziprasidone
- Where
- 22 sites in Italy
- Volunteers
- 147 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Treatment-resistant Schizophrenia
Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia
This is a prospective, 12-week, randomized, double-blind, placebo-controlled study, designed to evaluate the efficacy, safety, and tolerability of a dose of evenamide of 15 mg bid, compared to placebo, as add-on treatment in…
- Trial name
- ENIGMA-TRS 2 (NCT07184619)
- Testing
- Evenamide 15 mg bid
- Where
- 19 sites in United States, Argentina and 2 more
- Volunteers
- 400 people
- Sponsor
- Newron Pharmaceuticals SPA
Treatment-resistant Schizophrenia
Efficacy of Lu AF35700 in Patients With Early-in-disease or Late-in-disease Treatment-resistant Schizophrenia
This study evaluates the efficacy of 10 mg/day Lu AF35700 on symptoms of schizophrenia in patients with early-in-disease (ED) or late-in-disease (LD) treatment-resistant schizophrenia (TRS)
- Trial name
- Anew (NCT03230864)
- Testing
- Lu AF35700, Risperidone, Olanzapine
- Where
- 41 sites in United States, Bulgaria and 3 more
- Volunteers
- 119 people
- Sponsor
- H. Lundbeck A/S
Schizophrenia
The Effectiveness and Efficacy of the Combination of the Integrated Psychological Therapy and Metacognitive Training.
The combination of the Integrated Psychological Therapy and Metacognitive Training in individuals with schizophrenia and treatment resistant schizophrenia. Is it effective and efficacious?
- Trial name
- ATHSCHIZ (NCT05623228)
- Testing
- The combination of the Integrated Psychological Therapy and Metacognitive Training in individuals with schizophrenia and treatment resistant schizophrenia
- Where
- Greece
- Volunteers
- 35 people
- Sponsor
- Rakitzi, Stavroula
Refractory Schizophrenia
An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®, as an Add-on Therapy With Clozapine, for Residual Symptoms of Refractory Schizophrenia in Adults
This is an adaptive, Phase II/III study in 2 parts (i.e. Part 1 (dose ranging) and Part 2 (Hypothesis testing)). NaBen® is granted Breakthrough Therapy Designation by US FDA as treatment for refractory schizophrenia.
- Trial name
- NCT03094429
- Testing
- NaBen®
- Where
- United States
- Volunteers
- 287 people
- Sponsor
- SyneuRx International (Taiwan) Corp
Auditory Hallucination, Verbal, Treatment-resistant Schizophrenia
Comparaison of Avatar Therapy to Cognitive Behavioral Therapy in Schizophrenia With Treatment Refractory Hallucinations
Schizophrenia is associated with long-lasting health, social and financial burden for patients, families, caregivers and society.
- Trial name
- Phase3 (NCT04054778)
- Testing
- Avatar Therapy, Cognitive Behavioral Therapy
- Where
- Canada
- Volunteers
- 136 people
- Sponsor
- Ciusss de L'Est de l'Île de Montréal
Refractory Schizophrenia
Deep Brain Stimulation of the Nucleus Accumbens and Anterior Limb of the Internal Capsule in the Treatment of Refractory Schizophrenia
Schizophrenia is a lifelong psychiatric disorder with a prevalence rate of 0.559% and a lifetime prevalence rate of 0.588% among Chinese adults.
- Trial name
- NCT07369401
- Testing
- Deep Brain Stimulation
- Volunteers
- 10 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Treatment Resistant Schizophrenia
Comparison of Maintenance ECT Versus Clozapine in Treatment-resistant Schizophrenia
The proposed study will be conducted to compare the efficacy of maintenance ECT (M-ECT) vs Clozapine in treatment resistant schizophrenia (TRS) in terms of change in psychopathology measures and cerebral hemodynamics.
- Trial name
- NCT03807882
- Testing
- Bilateral M-ECT, Clozapine
- Where
- India
- Volunteers
- 60 people
- Sponsor
- All India Institute of Medical Sciences, Bhubaneswar
Schizophrenia, Schizoaffective Disorder
High Dose of Quetiapine in Treating Subjects With Treatment Refractory Schizophrenia or Schizoaffective Disorder
This study will investigate the safety and efficacy of quetiapine in sub-optimally responding patients with DSM-IV schizophrenia using a double blind, randomized 12-week trial comparing oral doses of 1200 mg/d to 600 mg/d of…
- Trial name
- HDQ (NCT00297947)
- Testing
- quetiapine
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Manhattan Psychiatric Center
Treatment Resistant Schizophrenia, Schizophrenia
Magnetic Seizure Therapy for Schizophrenia - Trial
This trial aims to assess the clinical effects and tolerability of Magnetic Seizure Therapy (MST) as an alternative to electroconvulsive therapy (ECT) for Treatment Resistant Schizophrenia (RS).
- Conditions
- Treatment Resistant Schizophrenia, Schizophrenia, Schizoaffective Disorder
- Trial name
- MAST (NCT06672588)
- Testing
- Magnetic Seizure Therapy (MST), Electroconvulsive Therapy (ECT)
- Where
- 2 sites in Canada
- Volunteers
- 80 people
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia, Treatment Resistant Disorders
Clozapine Versus Amisulpride in Treatment-resistant Schizophrenia Patients
Background: schizophrenia is a debilitating mental disorder affecting about 1% of the general population. About 30% of patients will not react to current drug treatment and defined as treatment-resistant schizophrenia patients…
- Trial name
- ClozAmi (NCT01448499)
- Testing
- Clozapine, Amisulpride, Clozapine+Amisulpride
- Where
- Israel
- Sponsor
- Geha Mental Health Center
Refractory Schizophrenia, Super Refractory Schizophrenia
Electroconvulsive Therapy (ECT) in Patients With Super Refractory Schizophrenia
Introduction: In spite of recent advances in schizophrenia treatment, 30% of patients still do not respond properly to antipsychotic therapy.
- Trial name
- SSURECT (NCT02049021)
- Testing
- MECTA SPECTRUM 5000Q ECT
- Where
- Brazil
- Volunteers
- 20 people
- Sponsor
- University of Sao Paulo
Schizophrenia
Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy
In this study, investigators designed a double-blind randomized trial to compare the efficacy and safety between sodium valproate, amisulpride and MECT combination therapy in clozapine-treated refractory schizophrenia (CTRS).
- Trial name
- NCT03652974
- Testing
- sodium valproate with Clozapine, modified electroconvulsive therapy(MECT) with Clozapine, amisulpride with Clozapine
- Where
- China
- Volunteers
- 145 people
- Sponsor
- Shanghai Mental Health Center
Treatment Resistant Disorders
Deep Brain Stimulation for Treatment-Resistant Schizophrenia
The purpose of this pilot study is to investigate the use of deep brain stimulation (DBS) of the substantia nigra pars reticulata (SNr) in subjects with treatment-resistant schizophrenia.
- Trial name
- NCT07592611
- Testing
- Medtronic Percept with SensSight Deep Brain Stimulation System
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Johns Hopkins University
Schizophrenia
Efficacy and Safety Study of Clozapine Augmented by Atomoxetine Versus Clozapine Augmented by Placebo in Patients With Chronic Resistant Schizophrenia
This is a randomized, placebo-controlled study to assess the efficacy and safety of ATX augmentation of CLZ as a treatment for the cognitive symptoms of schizophrenia.
- Trial name
- NCT00216281
- Where
- United States
- Volunteers
- 126 people
- Sponsor
- Indiana University
Treatment-resistant Schizophrenia
SMART Design to Compare Antipsychotic Treatments in Treatment-Resistant Schizophrenia
The project intends to take treatment-resistant schizophrenia as the research object and uses sequential multiple assignment randomized trial(SMART) design to define the treatment recommendations of different drug regimen for…
- Trial name
- NCT04528095
- Testing
- Clozapine, MECT, DBS
- Where
- China
- Volunteers
- 162 people
- Sponsor
- Shanghai Mental Health Center
Treatment-resistant Schizophrenia
The Characteristics of Treatment Resistant Schizophrenia From the Illness Onset
Previous long-term follow-up studies on patients with first-episode schizophrenia have shown that up to 30% of patients who have never received antipsychotic medication treatment do not experience symptom relief or have poor…
- Trial name
- NCT06128408
- Testing
- risperidone, olanzapine, aripiprazole
- Volunteers
- 300 people
- Sponsor
- Peking University
Schizophrenia, Schizoaffective Disorder
Minocycline Augmentation of Clozapine for Treatment Resistant Schizophrenia
This a randomized double-blind placebo controlled trial which aims to determine the beneficial effects of minocycline augmentation to clozapine in partial responders to Treatment Resistant Schizophrenia (TRS).
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- NCT02533232
- Testing
- Minocycline
- Where
- 4 sites in Pakistan
- Volunteers
- 60 people
- Sponsor
- Pakistan Institute of Living and Learning